Welcome to our dedicated page for Aytu Biopharma news (Ticker: AYTU), a resource for investors and traders seeking the latest updates and insights on Aytu Biopharma stock.
Aytu BioPharma, Inc. (AYTU) is a Nasdaq-listed pharmaceutical company focused on advancing medicines for complex central nervous system diseases, with an emphasis on major depressive disorder (MDD) and attention deficit-hyperactivity disorder (ADHD). Its news flow reflects this focus, highlighting commercial progress, clinical positioning and corporate developments around its prescription portfolio.
A central theme in Aytu’s recent news is EXXUA (gepirone) extended-release tablets, a novel oral selective serotonin 5HT1a receptor agonist indicated for the treatment of MDD in adults. Company announcements have covered the commercial availability of EXXUA in the United States, its status as the first and only 5HT1a agonist approved by the U.S. Food and Drug Administration for MDD, and integration of EXXUA distribution into Aytu’s RxConnect patient access platform.
Investors following AYTU news will also see updates on the company’s ADHD Portfolio and Pediatric Portfolio performance, including revenue trends and commentary from management in quarterly operational and financial results. Aytu’s press releases discuss net revenue by portfolio, gross profit, adjusted EBITDA and investments related to the EXXUA launch.
In addition, Aytu regularly announces participation in investor conferences, healthcare summits and dedicated Investor Day events. These items often feature presentations by senior management and key opinion leaders in psychiatry, focusing on EXXUA’s clinical profile, market opportunity and the company’s broader CNS strategy. For investors and observers, the AYTU news page provides a centralized view of product launches, patent developments, financing updates and ongoing investor outreach activities.
Summary not available.
Aytu BioPharma has received FDA approval for a Prior Approval Supplement allowing the transfer of Adzenys XR-ODT manufacturing to a contract manufacturer. This shift is anticipated to enhance product margins by approximately 15%. Following the successful completion of a bioequivalence study for Cotempla XR-ODT, the company plans to submit a site transfer PAS to the FDA by mid-2023, expecting approval by late 2023 or early 2024. CEO Josh Disbrow emphasized the significance of these milestones for improving ADHD product profitability. The manufacturing transition is expected to conclude by early 2024, facilitating the anticipated margin improvements. Aytu's ADHD product portfolio includes Adzenys and Cotempla, alongside other prescription and consumer health products.
Aytu BioPharma (NASDAQ:AYTU) reported strong financial results for Q2 2023, with net revenue reaching $26.3 million, a 14% increase year-over-year. The prescription (Rx) segment alone generated $18.0 million, a growth of 23% compared to the previous year, driven significantly by a 95% surge in pediatric product revenues.
Adjusted EBITDA was positive at $0.7 million, a significant improvement from the $(7.6) million loss reported last year. Despite challenges in the Consumer Health segment, which saw a 3% revenue decline, the company's strategic shift to higher-margin e-commerce sales is expected to bolster profitability.
Aytu BioPharma (Nasdaq:AYTU) is set to report its financial results for the quarter ended December 31, 2022, on February 21, 2023, after market close. The company specializes in pediatric-focused prescription medications and consumer health solutions. A conference call will follow the results at 5:00 pm ET on the same day, accessible via phone or webcast, with a replay available until March 7, 2023. Aytu's portfolio includes ADHD treatments like Adzenys XR-ODT and Cotempla XR-ODT, alongside consumer health products promoting various health needs. For more details, visit aytubio.com.
Aytu BioPharma (NASDAQ:AYTU) announced a delay in filing its Form 10-Q for the second quarter of fiscal year 2023, ending December 31, 2022. The delay is due to an assessment and management review concerning an accounting matter related to warrants issued in previous financings. The Company assures that this issue will not impact assets, cash, revenue, or operational metrics. Aytu plans to file the report as soon as possible and will reschedule its quarterly conference call. The Company focuses on pediatric prescription drugs and consumer health solutions.
Aytu BioPharma (NASDAQ:AYTU) has announced it will report its financial results for the second quarter of fiscal year 2023, ending December 31, 2022, on February 14, 2023, after market close. A conference call will take place the same day at 4:30 pm ET to discuss the results. Interested participants can join by calling (888) 506-0062 or (973) 528-0011 with access code 371594. A live webcast will be available and archived for 90 days. Aytu specializes in pediatric-focused prescription drugs and consumer health solutions, including treatments for ADHD and various vitamin products for children.
Aytu BioPharma, Inc. (NASDAQ:AYTU) has announced that it has regained compliance with Nasdaq's minimum bid price requirement. The notification from Nasdaq confirms that Aytu's common stock closed at $1.00 per share or higher for ten consecutive business days, from January 6 to January 20, 2023. The issue is now resolved as per Listing Rule 5550(a)(2). Aytu specializes in pediatric-focused prescription drugs and consumer health products, and its portfolio includes medications for ADHD, allergy relief, and vitamin supplementation for children. This compliance is a positive development for Aytu's market position.
Englewood, CO / ACCESSWIRE / January 24, 2023 / Aytu BioPharma (NASDAQ:AYTU) announces CEO Josh Disbrow will present at the Lytham Partners Investor Select Conference on January 31, 2023. The event will be held virtually, with a company webcast available at 9:00 am ET on the same day. The presentation can be accessed via the Aytu website. Additionally, management will hold one-on-one meetings with investors throughout the event. Interested parties can arrange meetings through Lytham Partners. Aytu specializes in pediatric-focused prescription drugs and consumer health solutions, including treatments for ADHD and various health products.
Aytu BioPharma is addressing the ongoing supply disruption of generic Adderall by promoting its FDA-approved bioequivalent, Adzenys XR-ODT. This medication is available as an orally disintegrating tablet, providing an alternative for ADHD patients unable to fill their Adderall prescriptions. Aytu's RxConnect program helps patients navigate insurance challenges, offering reduced out-of-pocket costs, often capped at $35 for commercially insured patients. The company emphasizes the importance of maintaining treatment continuity for individuals with ADHD during this time.
Aytu BioPharma (NASDAQ:AYTU) announced a 1-for-20 reverse stock split effective January 6, 2023, to regain compliance with Nasdaq's $1.00 minimum bid price requirement. This decision follows approval from stockholders at a Special Meeting on October 5, 2022. Post-split, approximately 68.8 million shares will be reduced to about 3.4 million. A cash payment will be made for any fractional shares. The compliance deadline is May 22, 2023, requiring a consistent closing bid price of at least $1.00 for ten consecutive business days.